MapLight Therapeutics

News

MapLight shares track up after $251m IPO

MapLight Therapeutics has made its debut on the Nasdaq, raising $251m for a lead drug that could be a rival to BMS' new schizophrenia drug Cobenfy.

News

Halozyme diversifies in drug delivery with Surf Bio buy

Halozyme has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio for up to $400m.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks